The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multi-omic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes.
 
Brian Warnecke
No Relationships to Disclose
 
Misako Nagasaka
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Genentech; Janssen; Lilly; Mirati Therapeutics; Novartis; Pfizer; Takeda
Speakers' Bureau - Blueprint Medicines; Janssen; Mirati Therapeutics; Mirati Therapeutics; Takeda
Research Funding - Tempus
Travel, Accommodations, Expenses - Anheart Therapeutics
 
Mohammed Najeeb Al Hallak
Speakers' Bureau - AstraZeneca; Guardant Health; Ipsen
(OPTIONAL) Uncompensated Relationships - CTI
 
Sahar Bannoura
No Relationships to Disclose
 
Chul Kim
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Daiichi Sankyo; Diffusion Pharmaceuticals; Eisai; Janssen; Jazz Pharmaceuticals; Mirati Therapeutics; Novartis; PierianDx; Sanofi
Research Funding - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Debiopharm Group; Genentech/Roche; Janssen; Karyopharm Therapeutics; Novartis; Regeneron
 
Andrew Elliott
Employment - Caris Life Sciences
 
Balazs Halmos
Consulting or Advisory Role - Apollomics; Arcus Biosciences; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Merck; Novartis; Pfizer; Takeda; Turning Point Therapeutics; Veracyte
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Dave S. Hoon
No Relationships to Disclose
 
Sourat Darabi
Honoraria - OncoLens
Consulting or Advisory Role - Bayer; BostonGene
 
Alex Patrick Farrell
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Ammar Sukari
Stock and Other Ownership Interests - Bristol-Myers Squibb/Pfizer; Merck
Honoraria - Merck Serono
Consulting or Advisory Role - Genentech
Speakers' Bureau - Eisai
 
Milan Radovich
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - LifeOmic
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - Combination therapy for the treatment of TNBC with a PI3K pathway inhibitor that targets PI3KDelta and PI3KGamma (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Emil Lou
Honoraria - Boston Scientific; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure
Research Funding - Intima; Novocure
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan
 
George W. Sledge
Leadership - Syndax; Tessa Therapeutics
Stock and Other Ownership Interests - Pionyr; Syndax; Tessa Therapeutics
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; G1 Therapeutics; GRAIL; Synaffix; Syndax; Verseau Therapeutics
Research Funding - Genentech/Roche (Inst); Pfizer (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Tessa Therapeutics; Verseau Therapeutics
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Chimerix; Oncoceutics; p53-Therapeutics; SMURF-Therapeutics
Consulting or Advisory Role - Rain Therapeutics
Research Funding - Chimerix; D&D Pharmatech
Patents, Royalties, Other Intellectual Property - Patent on therapeutic targeting on hypoxia-inducible factors; Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
(OPTIONAL) Uncompensated Relationships - As above
 
Asfar S. Azmi
Consulting or Advisory Role - Gerson Lehrman Group; Guidepoint Inc
Research Funding - Eisai; Janssen; Karyopharm Therapeutics